Therapeutics News and Research

RSS

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.

30 Jan 2021

Variants emerging during COVID-19 pandemic resist antibody neutralization

Researchers in the U.S. have warned that recently emerged variants of SARS-CoV-2 have become worryingly resistant to monoclonal antibody therapies, plasma from convalescent patients and sera from vaccinated individuals.

28 Jan 2021

Innovative breakthrough promises to diagnose DNA rearrangement mutations

Doctors are increasingly using genetic signatures to diagnose diseases and determine the best course of care, but using DNA sequencing and other techniques to detect genomic rearrangements remains costly or limited in capabilities.

28 Jan 2021

New tool offers data-driven, precision medicine approach to help scientists better understand COVID-19

It is called PAGER-CoV, and it promises to be an important tool in finding therapies for COVID-19.

27 Jan 2021

Vaccines delivered via skin may offer better protection against respiratory diseases

Among infectious diseases that have caused pandemics and epidemics, smallpox stands out as a success story. Smallpox vaccination led to the disease's eradication in the twentieth century.

27 Jan 2021

RENACER: New national hospital network aims to advance research on brain metastases

Last January 25th, the bylaws of the National Brain Metastasis Network (or RENACER, its acronym in Spanish) were signed and the network's first meeting was held.

27 Jan 2021

CDC researchers back U.S. school re-openings but with strict COVID-19 regulations

As the U.S. continues to grapple with surging cases and the complex logistics of mass vaccination, is the country in a position to fully re-open its schools for in-person learning? Researchers at the Centers for Disease Control and Prevention (CDC) think so – notwithstanding a few very important caveats.

27 Jan 2021

Study describes a safe potential therapeutic tool for liver regeneration

A new study led by researchers at the Center for Regenerative Medicine at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) now describes a safe new potential therapeutic tool for the recovery of liver function in chronic and acute liver diseases.

27 Jan 2021

Could spironolactone treat COVID-19-related pneumonia and pulmonary fibrosis?

Researchers have described the potential of the drug spironolactone, a potassium-sparing diuretic, and anti-androgen, in preventing or alleviating the severity of COVID-19 pneumonia, and in preventing pulmonary fibrosis.

27 Jan 2021

Allarity Therapeutics announces plans to test antiviral activity of stenoparib drug

Allarity Therapeutics of Hørsholm, Denmark, today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the "British variant"), at the COVID-19 Testing Service Center (CTSC) of Northern Arizona University's Pathogen and Microbiome Institute (PMI), a leading U.S. infectious disease testing center.

27 Jan 2021

Hybrid closed-loop insulin therapy improves glycemic control in adolescents, young adults

Hybrid closed-loop insulin therapy improved glycemic control in adolescents and young adults with type 1 diabetes. These outcomes, derived from the International Diabetes Closed-Loop (iDCL) Trial, are reported in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT).

27 Jan 2021

New compound may slow aging and age-related diseases

A compound that extends lifespan in a tiny nematode worm slows bone loss in aging mice. That surprising result comes from a longitudinal and functional study of 700 aging mice at the Buck Institute, a project that provides a treasure trove of data for researchers aiming to develop therapeutics to slow aging and age-related diseases.

27 Jan 2021

Researchers develop new computational method for studying genetic and environmental interactions

Researchers at Weill Cornell Medicine and Cornell University's Ithaca campus have developed a new computational method for studying genetic and environmental interactions and how they influence disease risk.

27 Jan 2021

Novel platform uses modified virus to combat pancreatic cancer

Researchers from Queen Mary University of London and Zhengzhou University have developed a powerful therapeutic platform that uses a modified virus for the treatment of pancreatic cancer.

26 Jan 2021

New NIH grant supports research on Alzheimer's disease caused by gene mutations

A new grant from the National Institute On Aging at the National Institutes of Health will support ongoing research at Rensselaer Polytechnic Institute to address Alzheimer's disease caused by gene mutations.

26 Jan 2021

£1.6 million grant awarded to advance development of MND drug candidate

Researchers from the University of Sheffield's Institute for Translational Neuroscience have been awarded a £1.6 million grant from the Medical Research Council.

26 Jan 2021

Elevated levels of certain immune cells in the blood linked to COVID-19 severity

Individual variations in how the immune system responds to SARS-CoV-2 appear to impact the severity of disease.

26 Jan 2021

Why even presidential pressure might not get more vaccine to market faster

Americans are dying of covid-19 by the thousands, but efforts to ramp up production of potentially lifesaving vaccines are hitting a brick wall.

26 Jan 2021

Drug intervention may prevent heart damage caused by chemotherapy

There could be an intervention on the horizon to help prevent heart damage caused by the common chemotherapy drug doxorubicin, new research suggests.

26 Jan 2021

SARS-CoV-2 rapidly adapts to Vero E6 cell culture propagation

Researchers at the Erasmus Medical Centre in the Netherlands and the University of Illinois at Urbana-Champaign in the US found that SARS-CoV-2 rapidly adapts to Vero E6 cell culture propagation and that this can be prevented by using cell lines with an active serine protease-mediated entry pathway.

26 Jan 2021

Therapeutics News and Research

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

Variants emerging during COVID-19 pandemic resist antibody neutralization

Innovative breakthrough promises to diagnose DNA rearrangement mutations

New tool offers data-driven, precision medicine approach to help scientists better understand COVID-19

Vaccines delivered via skin may offer better protection against respiratory diseases

RENACER: New national hospital network aims to advance research on brain metastases

CDC researchers back U.S. school re-openings but with strict COVID-19 regulations

Study describes a safe potential therapeutic tool for liver regeneration

Could spironolactone treat COVID-19-related pneumonia and pulmonary fibrosis?

Allarity Therapeutics announces plans to test antiviral activity of stenoparib drug

Hybrid closed-loop insulin therapy improves glycemic control in adolescents, young adults

New compound may slow aging and age-related diseases

Researchers develop new computational method for studying genetic and environmental interactions

Novel platform uses modified virus to combat pancreatic cancer

New NIH grant supports research on Alzheimer's disease caused by gene mutations

£1.6 million grant awarded to advance development of MND drug candidate

Elevated levels of certain immune cells in the blood linked to COVID-19 severity

Why even presidential pressure might not get more vaccine to market faster

Drug intervention may prevent heart damage caused by chemotherapy

SARS-CoV-2 rapidly adapts to Vero E6 cell culture propagation

Event guide: The Non-Opioid Pain Therapeutics Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News